

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

**Growth-Environment Dependent Modulation of *Staphylococcus aureus* Branched-Chain to Straight-Chain Fatty Acid Ratio and Incorporation of Unsaturated Fatty Acids**

**Suranjana Sen, Seth R. Johnson, Yang Song, Sirisha Sirobhushanam, Ryan Tefft, Craig Gatto, and Brian J. Wilkinson\***

School of Biological Sciences, Illinois State University, Normal, Illinois, United States of America

*E-mail:* [bjwilkin@ilstu.edu](mailto:bjwilkin@ilstu.edu)

**Funding:** This work was funded in part by grant 1R15AI099977 to Brian Wilkinson and Craig Gatto and grant 1R15GM61583 to Craig Gatto from the National Institutes of Health

## 24 **Abstract**

25       The fatty acid composition of membrane glycerolipids is a major determinant of  
26 *Staphylococcus aureus* membrane biophysical properties that impacts key factors in cell  
27 physiology including susceptibility to membrane active antimicrobials, pathogenesis, and  
28 response to environmental stress. The fatty acids of *S. aureus* are considered to be a mixture of  
29 branched-chain fatty acids (BCFAs), which increase membrane fluidity, and straight-chain fatty  
30 acids (SCFAs) that decrease it. The balance of BCFAs and SCFAs in strains USA300 and  
31 SH1000 was affected considerably by differences in the conventional laboratory medium in  
32 which the strains were grown with media such as Mueller-Hinton broth and Luria broth resulting  
33 in high BCFAs and low SCFAs, whereas growth in Tryptic Soy Broth and Brain-Heart Infusion  
34 broth led to reduction in BCFAs and an increase in SCFAs. Straight-chain unsaturated fatty acids  
35 (SCUFAs) were not detected. However, when the organism was grown *ex vivo* in serum, the  
36 fatty acid composition was radically different with SCUFAs, which increase membrane fluidity,  
37 making up a substantial proportion of the total (<25%) with SCFAs (>37%) and BCFAs (>36%)  
38 making up the rest. Staphyloxanthin, an additional major membrane lipid component unique to *S.*  
39 *aureus*, tended to be greater in content in cells with high BCFAs or SCUFAs. Cells with high  
40 staphyloxanthin content had a lower membrane fluidity that was attributed to increased  
41 production of staphyloxanthin. *S. aureus* saves energy and carbon by utilizing host fatty acids for  
42 part of its total fatty acids when growing in serum. The fatty acid composition of *in vitro* grown  
43 *S. aureus* is likely to be a poor reflection of the fatty acid composition and biophysical properties  
44 of the membrane when the organism is growing in an infection in view of the role of SCUFAs in  
45 staphylococcal membrane composition and virulence.

46

## 47 **Introduction**

48 *Staphylococcus aureus* is a worldwide significant pathogen in the hospital and the  
49 community. Antibiotic resistance has developed in waves [1] such that we now have methicillin-  
50 resistant *S. aureus* (MRSA), vancomycin-resistant *S. aureus* (VRSA) and vancomycin-  
51 intermediate *S. aureus* (VISA) [2, 3]. Given the threat of multiply antibiotic-resistant *S. aureus*,  
52 various aspects of staphylococcal biology including pathogenicity, antibiotic resistance, and  
53 physiology are currently being investigated intensively, in part to support the search for novel  
54 anti-staphylococcal agents.

55 The bacterial cytoplasmic membrane forms an essential barrier to the cell and is  
56 composed of a glycerolipid bilayer with associated protein molecules, and is a critical  
57 determinant of cell physiology. The biophysical properties of the membrane are to a large extent  
58 determined by the fatty acyl residues of membrane phospholipids and glycolipids [4, 5]. The  
59 lipid acyl chains influence membrane viscosity/fluidity, and impact the ability of bacteria to  
60 adapt to changing environments, the passive permeability of hydrophobic molecules, active  
61 transport, and the function of membrane-associated proteins [4-6]. Additionally, membrane fatty  
62 acid composition has a major influence on bacterial pathogenesis, critical virulence factor  
63 expression [7], and broader aspects of bacterial physiology [8].

64 *S. aureus* membrane fatty acids are generally considered to be a mixture of branched-  
65 chain fatty acids (BCFAs) and straight-chain fatty acids (SCFAs) [9-11], and for a  
66 comprehensive review of earlier literature see [12]. Typically, *S. aureus* contains about 65%  
67 BCFAs and 35% SCFAs. In *S. aureus* the major BCFAs are odd-numbered iso and anteiso fatty  
68 acids with one methyl group at the penultimate and antepenultimate positions of the fatty acid

69 chains, respectively (Fig. 1). BCFAs have lower melting points than equivalent SCFAs and cause  
70 model phospholipids to have lower phase transition temperatures [13], and disrupt the close  
71 packing of fatty acyl chains [14, 15]. The membrane lipid composition of *S. aureus* is further  
72 complicated by the presence of staphyloxanthin, a triterpenoid carotenoid with a C30 chain with  
73 the chemical name of  $\alpha$ -D-glucopyranosyl-1-O-(4,4'-diaponeurosporen-4-oate)-6-O (12-  
74 methyltetradecanoate) [16] (Fig. 1). Staphyloxanthin, as a polar carotenoid, is expected to have a  
75 significant influence on membrane properties with the expectation that it rigidifies the membrane  
76 [17], and Bramkamp and Lopez [18] have suggested that staphyloxanthin is a critical component  
77 of lipid rafts in *S. aureus* incorporating the organizing protein flotillin. Staphyloxanthin has  
78 drawn considerable attention in recent years as a possible virulence factor by detoxifying  
79 reactive oxygen species produced by phagocytic cells [19, 20], and as a potential target for  
80 antistaphylococcal chemotherapy [21].

81 **Fig 1. Structures of major fatty acids and staphyloxanthin of the *S. aureus* cell membrane.**

82 In our laboratory, we are interested in the mechanisms of action of and resistance to novel  
83 and existing anti-staphylococcal antimicrobials [22-24]. Because much antibiotic work employs  
84 Mueller-Hinton (MH) medium, [25] we had occasion to determine the fatty acid composition of  
85 a *S. aureus* strain grown in this medium. The analysis was carried out using the MIDI microbial  
86 identification system (Sherlock 4.5 microbial identification system; Microbial ID, Newark, DE,  
87 USA), [26]. We were taken aback when the fatty acid profile came back showing a very high  
88 percentage (84.1%) of BCFAs, and the organism was not even identified by MIDI as a *S. aureus*  
89 strain. In a previous study where we grew *S. aureus* in BHI broth we found that 63.5% of the  
90 fatty acids were BCFAs, and 32.4% were SCFAs [10]. This is a much more typically observed

91 balance between BCFAs and SCFAs in previous studies of the fatty acid composition of *S.*  
92 *aureus* [9- 12].

93 A range of different media are used for cultivating *S. aureus* in studies from different  
94 laboratories [27]. These are mostly complex media such as TSB, Brain Heart Infusion (BHI)  
95 broth, MH broth, Luria-Bertani (LB) broth, and, much more rarely, defined media [11]. Ray et  
96 al. [27] and Oogai et al [28] have pointed out that different media have major, but largely  
97 unstudied and ignored, effects on the expression of selected target virulence and regulatory  
98 genes. Although seemingly prosaic at first glance, issues of choice of strain and medium are  
99 nevertheless critical considerations in staphylococcal research [29]. These authors, in their recent  
100 protocol publication on the growth and laboratory maintenance of *S. aureus*, have suggested that  
101 TSB and BHI media are the media of choice for staphylococcal research. In light of recent  
102 literature in various microorganisms, it is becoming glaringly evident that environment has a  
103 tremendous effect on the physiology of different pathogens; hence cells from *in vivo* are  
104 drastically different from *in vitro* cultured ones. Such distinctions are likely important for  
105 studying antimicrobial susceptibilities, drug resistances and pathogenesis.

106 We decided to carry out a systematic study of the impact of growth medium on the fatty  
107 acid and carotenoid composition of *S. aureus* given the large potential impact of these  
108 parameters on membrane biophysical properties and its further ramifications. The BCFA: SCFA  
109 ratio was significantly impacted by the laboratory medium used, with media such as MH broth  
110 encouraging high proportions of BCFAs. However, strikingly, when cells were grown in serum,  
111 an *ex vivo* environment, the fatty acid composition changed radically, with straight-chain  
112 unsaturated fatty acids (SCUFAs), which were not detected in cells grown in laboratory media,  
113 making up a major proportion of the total fatty acids. Biosynthesized bacterial fatty acids are

114 produced by fatty acid synthase II (FASII) [30]. However, fatty acid biosynthesis is expensive in  
115 terms of energy and carbon, and many bacteria are able to incorporate extracellular fatty acids  
116 into their membrane lipids to varying degrees [30]. This extreme plasticity of *S. aureus*  
117 membrane lipid composition is undoubtedly important in determining membrane physical  
118 structure and thereby the functional properties of the membrane. The alterations in the fatty acid  
119 composition as a result of interactions of the pathogen with the host environment may be a  
120 crucial factor in determining its fate in the host. Typically used laboratory media do not result in  
121 a *S. aureus* membrane fatty acid composition that closely resembles the likely one of the  
122 organism growing *in vivo* in a host.

## 123 **Materials and Methods**

### 124 **Bacterial strains and growth conditions**

125 The primary *S. aureus* strains studied were USA300 and SH1000. USA300 is a  
126 community-acquired MRSA strain, and is a leading cause of aggressive cutaneous and systemic  
127 infections in the USA [1, 31, 32]. This clinical MRSA also has a well-constructed diverse  
128 transposon mutant library [33]. *S. aureus* strain SH1000, is an 8325-line strain that has been used  
129 extensively in genetic and pathogenesis studies [34]. The laboratory media used were MH broth,  
130 TSB and Luria Broth (LB) from Difco. For growth and fatty acid composition studies cultures of  
131 *S. aureus* strains were grown at 37° C in 250 ml Erlenmeyer flasks containing each of the  
132 different laboratory media with a flask-to-medium volume ratio of 6:1. Growth was monitored  
133 by measuring the OD<sub>600</sub> at intervals using a Beckman DU-65 spectrophotometer.

### 134 **Growth of *S. aureus* in serum**

135 Sterile fetal bovine serum of research grade was purchased from Atlanta Biologics, USA.  
136 The aliquoted serum was incubated in a water bath at 56° C for 30 min to heat inactivate the

137 complement system. *S. aureus* cells were grown for 24 hours in 50 ml of serum in a 250 ml flask  
138 at 37°C with shaking at 200 rpm.

139

#### 140 **Analysis of the membrane fatty acid composition of *S. aureus* grown in different media**

141 The cells grown in the different laboratory media conventionally used were harvested in  
142 mid-exponential phase (OD<sub>600</sub> 0.6), and after 24 hrs of growth in serum, by centrifugation at  
143 3000 x g at 4° C for 15 minutes and the pellets were washed three times in cold distilled water.  
144 The samples were then sent for fatty acid methyl ester (FAME) analysis whereby the fatty acids  
145 in the bacterial cells (30-40 mg wet weight) were saponified, methylated, and extracted. The  
146 resulting methyl ester mixtures were then separated using an Agilent 5890 dual-tower gas  
147 chromatograph and the fatty acyl chains were analyzed and identified by the Midi microbial  
148 identification system (Sherlock 4.5 microbial identification system) at Microbial ID, Inc.  
149 (Newark, DE) [26]. The percentages of the different fatty acids reported in the tables are the  
150 means of the values from three separate batches of cells under each condition. The standard  
151 deviations are ±1.5 or less. Some minor fatty acids such as odd-numbered SCFAs are not  
152 reported.

#### 153 **Extraction and estimation of carotenoids**

154 For quantification of the carotenoid pigment in the *S. aureus* cells grown in different  
155 media, the warm methanol extraction protocol was followed as described by Davis et al.  
156 [35]. Cultures of *S. aureus* were harvested at mid-exponential phase and were washed with  
157 cold water. The pellets were then extracted with warm (55°C) methanol for 5 min. The  
158 OD<sub>465</sub> of the supernatant after centrifugation was measured using a Beckman DU 70  
159 spectrophotometer. Determinations were carried out in triplicate.

## 160 **Measurement of the fluidity of the *S. aureus* membrane**

161           The fluidity of the cell membrane of the *S. aureus* strains grown in different media  
162 were determined by anisotropic measurements using the fluorophore diphenylhexatriene  
163 (DPH) following the protocol described previously [36]. Mid exponential phase cells grown in  
164 respective media and serum were harvested and washed with cold sterile PBS (pH 7.5).The  
165 pellets were then resuspended in PBS containing 2  $\mu$ M DPH (Sigma, MO) to an OD<sub>600</sub> of  
166 about 0.3 and incubated at room temperature in the dark for 30 min. Fluorescence polarization  
167 emitted by the fluorophore was measured using a PTI Model QM-4 Scanning  
168 Spectrofluorometer at an excitation wavelength of 360 nm and emission wavelength of 426  
169 nm. The experiments were performed with three separate fresh batches of cells and the Student  
170 T-test of the mean polarization values was used to determine statistically significant  
171 differences.

## 172 **Results**

### 173 **MH broth and LB increase the content of BCFAs and TSB and BHI broth increase the** 174 **content of SCFAs**

175           The fatty acid compositions of strain USA300 grown in different laboratory media are  
176 shown in Table 1. Growth in MH broth and LB broth resulted in a high content of BCFAs-  
177 80.9% and 77.2% respectively, whereas SCFAs were 19.1% and 22.8% respectively. However,  
178 in TSB and BHI broth the BCFAs contents were lower at 51.7% and 51.5% respectively, and  
179 SCFAs were increased to 48.3 and 48.5% respectively. In MH broth anteiso odd-numbered  
180 fatty acids were the major fatty acids in the profile (59.8%), followed by even numbered  
181 SCFAs (16.6%), iso odd-numbered fatty acids (15.8%), with iso even-numbered fatty acids  
182 making up only a minor portion (4.7%). Anteiso C15:0 was the predominant fatty acid in the

183 membrane lipids (39%). This particular fatty acid has a significant impact on fluidizing  
 184 membranes [37, 38]. The anteiso fatty acids were significantly reduced in TSB-grown cells  
 185 (29.3%). The major SCFAs in TSB-grown cells were C18:0 and C20:0 at 19.1% and 18.6%  
 186 respectively. Overall, the fatty acid compositions were in line with many previous studies of *S.*  
 187 *aureus* fatty acid composition [9-12], but we are unaware of previous studies that have  
 188 identified this impact of medium on the proportions of BCFAs and SCFAs in the membrane.

189 **Table 1. The membrane fatty acid profile of *S. aureus* USA300**

190 % (wt/wt) of total fatty acids

<i>Growth Medium</i>	<i>Anteiso odd</i>				<i>Iso odd</i>				<i>Iso even</i>				<i>Straight Even</i>					<i>BCFA</i>	<i>SCFA</i>
	<i>C15:0</i>	<i>C17:0</i>	<i>C19:0</i>	<i>SUM</i>	<i>C15:0</i>	<i>C17:0</i>	<i>C19:0</i>	<i>SUM</i>	<i>C14:0</i>	<i>C16:0</i>	<i>C18:0</i>	<i>SUM</i>	<i>C14:0</i>	<i>C16:0</i>	<i>C18:0</i>	<i>C20:0</i>	<i>SUM</i>		
<b>BHI</b>	28.5	2.6	ND	31.1	12.2	1.8	ND	14	2.9	1.4	ND	4.3	3.3	7.9	21.5	13.4	46.1	51.5	48.5
<b>TSB</b>	26.9	2.4	ND	29.3	12.8	2	ND	14.8	3.7	1.8	ND	5.5	2.3	6.4	19.1	18.6	46.4	51.7	48.3
<b>MHB</b>	39	15	5.8	59.8	7.7	4.9	3.2	15.8	1	2.1	1.6	4.7	1.1	1.8	6.5	7.2	16.6	80.9	19.1
<b>LB</b>	36.5	11	2.4	49.9	13.3	6.6	2.6	22.5	1.4	2.2	1	4.6	ND	3	10	6.9	19.9	77.2	22.8

191

192 ND- Not detected

193 The results of a similar series of experiments with strain SH1000 are shown in Table 2.

194 Overall, the proportion of BCFAs of this strain was higher than strain USA300. In strain

195 SH1000 the BCFAs were higher than USA300 in all media- BHI 66.6%, TSB 68.5%, with

196 particularly high contents in MH broth 90.2% and LB 89%. The proportion of SCFAs was

197 correspondingly smaller in all cases compared to strain USA300. Anteiso fatty acids were the

198 major class of fatty acids in all media, amongst which anteiso C15:0 was present in the

199 highest amount in all cases. However, the same phenomenon was noted where MH broth and

200 LB encouraged a high proportion of BCFAs, low SCFAs, and TSB and BHI had the opposite  
 201 effects on fatty acid composition. Two additional media were studied with this strain. Both  
 202 Tryptone broth [39] and defined medium [40] resulted in high BCFAs (80.4% and 85%  
 203 respectively), and low SCFAs (19.7% and 15% respectively).

204

205 **Table 2. The membrane fatty acid composition of *S. aureus* strain SH1000**

206 % (wt/wt) of total fatty acid

<i>Growth Medium</i>	<i>Anteiso odd</i>				<i>Iso odd</i>				<i>Iso even</i>				<i>Straight Even</i>					<i>BCFA</i>	<i>SCFA</i>
	C15:0	C17:0	C19:0	SU	C15:0	C17:0	C19:0	SU	C14:0	C16:0	C18:0	SU	C14:0	C16:0	C18:0	C20:0	SU		
<b>BHI</b>	33.6	6.4	1	41	15.7	4.3	N	20	2.6	3.1	N	5.7	2.7	8.1	15.2	6.4	41	66.6	33.4
<b>TSB</b>	31.6	6	N	37.6	18.7	5.2	1.2	25.1	2.2	2.7	N	4.9	2	7.8	15.4	6.3	31.5	68.5	31.5
<b>MHB</b>	43.7	20.7	5.7	70.1	6.8	5.1	2.3	14.2	1.2	3.1	1.6	5.9	N	1.4	4.2	2.3	7.9	90.2	9.8
<b>LB</b>	42.8	16.1	3.1	61.9	12.2	7.2	2.3	21.7	1.3	2.9	1.2	5.4	N	2.4	6	2.6	11	89	11

207 ND- Not detected

208 The phenomenon of higher BCFAs in MH broth-grown cells and higher SCFAs in TSB  
 209 grown cells was observed in 8 out of 9 strains tested which included MRSA, VISA and  
 210 daptomycin decreased susceptibility strains (data not shown). This indicates that the  
 211 phenomenon noted in strains USA300 and SH1000 also extends to other *S. aureus* strains.

212 **The fatty acid composition of *S. aureus* grown *ex vivo* in serum is radically different to**  
 213 **those of the organism grown in laboratory media**

214 It was of interest to try and get an idea of the fatty acid composition of *S. aureus* grown  
 215 *in vivo*. Strain USA300 and SH1000 were grown in serum, which resulted in major changes in

216 the fatty acid profile (Table 3). Total BCFAs were reduced to 37.5% in USA300 and 36.3 in  
 217 SH1000; SCFAs were at 37.8% in USA300 and 32.1% in SH1000, but 25% of the fatty acid  
 218 profile in the case of USA300 and 30.6% in SH1000 was accounted for by SCUFAs.  
 219 Strikingly, this type of fatty acid was not present in the profile of the organism when grown in  
 220 laboratory media. Interestingly, BCFAs and SCUFAs have similar effects in increasing fluidity  
 221 of the membrane [4].

222 **Table 3. The membrane fatty acid compositions of *S. aureus* USA300 and SH1000 grown *ex***  
 223 ***vivo* in serum**

224 % (wt/wt) of total fatty acid

Membrane fatty acids		Strain USA300	Strain SH1000
<i>Anteiso odd</i>	C15:0	21	18.2
	C17:0	4	3
	Sum	25	21.2
<i>Iso odd</i>	C15:0	7.1	6
	C17:0	2	1.8
	Sum	9.1	7.8
<i>Iso even</i>	C14:0	1.7	2.4
	C16:0	1.7	1.6
	Sum	3.4	4
<i>Straight even</i>	C14:0	1.7	1.1
	C16:0	16.4	13.2
	C18:0	13.3	12.1
	C20:0	4.8	4.4
	Sum	36.2	30.8
<i>Straight odd</i>		1.6	1.3
<i>Unsaturated fatty acids</i>	C16:1 $\Delta$ 9	1.7	1.5
	C18:1 $\Delta$ 9	16	15.4
	C18:1 $\Delta$ 7	4.2	6.4
	C20:1 $\Delta$ 9	2.1	5
	Sum	25	30.6
<i>BCFAs</i>		37.5	36.3
<i>SCFAs</i>		37.8	32.1
<i>SCUFAs</i>		25	30.6

225

## 226 **Carotenoid content of cells grown in different media**

227 Staphyloxanthin is another significant membrane component that might impact the  
228 biophysical properties of the membrane. Accordingly, the carotenoid content of cells grown in  
229 different media were determined and the results are shown in Fig. 2. Strain SH1000 cells  
230 grown in MH broth had a much higher carotenoid content than cells grown in the other media.  
231 The pellets of cells grown in this particular media were noticeably yellow. It is possible that  
232 the carotenoid content rises to counterbalance the potentially high fluidity of MH broth-grown  
233 cells with their high content of BCFAs, specifically mainly anteiso fatty acids. LB (high  
234 BCFAs) and serum (high SCUFAs) - grown cells had higher carotenoid contents than TSB or  
235 BHI broth –grown cells. In strain USA300 MHB- and serum-grown cells also had higher  
236 carotenoid contents than did cells grown in BHI, TSB or LB. In general this strain was less  
237 pigmented than strain SH1000.

## 238 **Fig 2. Influence of growth environment on the carotenoid content of *S. aureus*.**

239 The strains, USA300 (black columns) and SH1000 (blue columns), were grown in different  
240 growth media and the carotenoid was estimated after extraction by warm methanol.

## 241 **Membrane fluidity of *S. aureus* cells with different fatty acid compositions**

242 The membrane fluidity of cells of strain SH1000 grown in BHI broth, LB and TSB  
243 were very similar (0.185-0.19) as shown in Fig. 3. The membranes of MH-broth and serum-  
244 grown cells, 0.25 and 0.248 were significantly less fluid than cells grown in the other media.  
245 Possibly the higher carotenoid contents of cells grown in MH broth and serum rigidifies the  
246 membrane. Strain USA300 also showed a similar pattern of membrane fluidity in the different  
247 growth media Fig. 3. The membrane fluidity of both strains was highest in cells grown in LB,  
248 consistent with the high content of BCFAs. Furthermore, there was no accompanying increase  
249 in staphyloxanthin content with its possible membrane rigidifying effect in contrast to MHB or

250 serum-grown cells.

251 **Fig 3. Influence of growth environment on the membrane fluidity of *S. aureus* cells.**

252 The strains, USA300 (black columns) and SH1000 (blue columns), were grown in the different  
253 media to mid exponential phase and membrane anisotropy was measured by fluorescence  
254 polarization.

255 **Discussion**

256 From numerous studies over the past several decades of *S. aureus* grown *in vitro* in  
257 various laboratory media it is considered that the membrane fatty acid composition of the  
258 organism is a mixture of BCFA and SCFAs [9-12], and BCFAs have generally been found to  
259 be predominant. Through study of a range of different conventional growth media, certain  
260 media were found to encourage a higher proportion of BCFAs than others, whereas in some  
261 media the proportion of SCFAs was increased. This may have significant physiological  
262 ramifications given the opposing effects of BCFAs and SCFAs on membrane fluidity with  
263 BCFAs fluidizing and SCFAs rigidifying the membrane [4]. However, there was a radical  
264 change in the entire fatty acid composition when the organism was grown *ex vivo* in serum  
265 with SCUFAs appearing in the profile in significant amounts accompanied with a decrease in  
266 BCFA content.

267 It is useful to discuss our fatty acid compositional data in the context of what is known  
268 about phospholipid biosynthesis and the positional distribution of fatty acids on the 1 and 2  
269 carbon atoms of the glycerol residue (Fig. 4). Phosphatidic acid is a key intermediate in the  
270 biosynthesis of the *S. aureus* phospholipids, which are phosphatidyl glycerol, cardiolipin and  
271 lysyl-phosphatidyl glycerol [5]. Our current knowledge of the pathway of phospholipid  
272 biosynthesis and the incorporation of exogenous and endogenous fatty acids is summarized in  
273 Fig. 4 [41]. Phosphatidic acid (PtdOH), the universal precursor of phospholipids, is  
274 synthesized by the stepwise acylation of *sn*-glycerol-3-phosphate first by PlsY that transfers a

275 fatty acid to the 1-position from acyl phosphate. The 2-position is then acylated by PlsC  
276 utilizing acyl-ACP. Acyl-ACP is produced by the FASII pathway and PlsX catalyses the  
277 interconversion of acyl-ACP and acyl phosphate. Exogenous fatty acids readily penetrate the  
278 membrane and are activated by a fatty acid kinase to produce acyl phosphate that can be  
279 utilized by PlsY, or they can be converted to acyl-ACP for incorporation into the 2-position by  
280 PlsC. Exogenous fatty acids can also be elongated by the FASII pathway. When *S. aureus* is  
281 grown in medium that results in a high proportion of BCFAs the major phospholipid,  
282 phosphatidyl glycerol (PtdGro), has, almost exclusively, anteiso C17:0 at position 1 and  
283 anteiso C15:0 at position 2 [42]. Growth in the presence of oleic acid (C18:1 $\Delta$ 9) showed  
284 anteiso C17:0 at position 1 was replaced by C18:1 $\Delta$ 9 and C20:1 $\Delta$ 11, whereas the anteiso  
285 C15:0 at position 2 remained at about 50%. BCFAs are not present in serum and hence must be  
286 biosynthesized from 2-methylbutyryl CoA, most likely produced from isoleucine.

287 **Fig 4. Pathway of phospholipid biosynthesis and the incorporation of exogenous and**  
288 **endogenous fatty acids in *S. aureus*.**

289 Phosphatidic acid (PtdOH), the universal precursor of phospholipids, is synthesized  
290 by the stepwise acylation of *sn*-glycerol-3-phosphate first by PlsY that transfers a fatty acid to  
291 the 1-position from acyl phosphate. The 2-position is then acylated by PlsC utilizing acyl-ACP.  
292 Acyl-ACP is produced by the FASII pathway and PlsX catalyses the interconversion of acyl-  
293 ACP and acyl phosphate. Exogenous fatty acids readily penetrate the membrane and are  
294 activated by a fatty acid kinase ( FakB1 for SCFAs and FakB2 for SCUFAs) to produce acyl  
295 phosphate that can be utilized by PlsY, or that can be converted to acyl-ACP for incorporation  
296 into the 2-position by PlsC. Exogenous fatty acids can also be elongated by the FASII pathway.  
297 Figure modified from Parsons et al. [41].

298

299 **What determines the balance between BCFAs and SCFAs in cells grown in laboratory**  
300 **media?**

301 MH medium leads to high proportion of BCFAs in the staphylococcal cells whereas  
302 growth in TSB leads to an increase in the proportion of SCFAs. MH broth (Difco) is composed

303 of beef extract powder (2 g/l), acid digest of caseine (17.5 g/l), and soluble starch (1.5 g/l). Thus,  
304 by far the major medium component is acid digest of caseine, and this is expected to be high in  
305 free amino acids. TSB (Difco) is composed of pancreatic digest of caseine (17 g/l), enzymatic  
306 digest of soybean meal (3 g/l), dextrose (2.5 g/l), sodium chloride (5 g/l) and dipotassium  
307 phosphate (2.5 g/l). The major components then of TSB are a mixture of peptides formed by  
308 enzymatic digestion of caseine and soybean meal. Payne and Gilvarg [43] fractionated Bacto  
309 Neopeptone using gel filtration. They found that peptides with a molecular weight below 650  
310 represented about 25% of the mixture, and free amino acids were about 1 % of the entire  
311 preparation. We believe that the free amino acids from the acid digest of casein can have a  
312 dominant effect on the fatty acid composition.

313 *Listeria monocytogenes* is a Gram-positive bacterium with a very high (90%)  
314 proportion of BCFAs in its cell membrane. The fatty acid composition of the organism grown in  
315 defined medium not containing any branched-chain amino acids was readily modified by  
316 exogenous isoleucine or leucine, which resulted in the fatty acid profile being dominated by  
317 anteiso odd and iso odd fatty acids respectively [26]. *L. monocytogenes* can also obtain amino  
318 acids by metabolism of peptides that are taken up [44] as can *S. aureus* [45]. It may be that  
319 transport of free branched-chain amino acids results in higher pool levels than when they are  
320 biosynthesized or produced through metabolism of transported peptides, giving them a dominant  
321 effect on fatty acid composition. In *S. aureus* supplementation of medium with 2-methylbutyrate,  
322 a precursor of anteiso fatty acids, significantly increased the content of anteiso C15:0 and C17:0  
323 [10]. Mutants of *S. aureus* in the transporters of leucine and valine lacked odd and even  
324 numbered fatty acids derived from these amino acids [46].

325 Growth in media such as TSB and BHI lead to a higher proportions of SCFAs than  
326 media such as MH broth, although SCUFAs were not detected. The origin of SCFAs is not clear  
327 as to whether they originate from the medium or are biosynthesized. Typically in bacteria SCFAs  
328 are biosynthesized from acetyl CoA via the activities of FabH. However, acetyl CoA was a poor  
329 substrate for *S. aureus* FabH [47], whereas the enzyme had high activity for butyryl CoA raising  
330 the possibility that butyrate is the primer for biosynthesis of SCFAs in *S. aureus*. It is also  
331 possible that SCFAs that may be present in TSB and BHI may be utilized directly for fatty acid  
332 elongation to the SCFAs in the membrane typical of growth in these media.

### 333 **The underappreciated ability of *S. aureus* to incorporate host fatty acids from serum**

334 A striking finding in our paper is that *S. aureus* has the capacity to incorporate large  
335 proportions of SCFAs and SCUFAs when grown *ex vivo* in serum. Earlier reports of *S. aureus*  
336 fatty acid composition have not reported significant amounts of SCUFAs in *S. aureus* [9-12].  
337 Indeed it appears that *S. aureus* lacks the genes necessary to biosynthesize unsaturated fatty acids  
338 [41]. However an early report by Altenbern [48] showed that inhibition of growth by the fatty  
339 acid biosynthesis inhibitor cerulenin could be relieved by SCFAs or SCUFAs, implying *S.*  
340 *aureus* had the ability to incorporate preformed fatty acids. Fatty acid compositional studies of  
341 the cells were not reported though. Serum is lipid rich [49-51] and a comprehensive analysis of  
342 the human serum metabolome including lipids has recently been published [52]. BCFAs are  
343 present, if at all, in only very small amounts in serum. Bacterial pathogens typically have the  
344 ability to incorporate host-derived fatty acids thereby saving carbon and energy since fatty acids  
345 account for 95% of the energy requirement of phospholipid biosynthesis [30].

346           The FASII pathway has been considered to be a promising pathway for inhibition  
347 with antimicrobial drugs. The viability of FASII as a target for drug development was challenged  
348 by Brinster et al. [53] especially for bacteria such as streptococci where all the lipid fatty acids  
349 could be replaced by SCFAs and SCUFAs from serum. However, Parsons et al. [42] showed that  
350 exogenous fatty acids could only replace about 50% of the phospholipid fatty acids in *S. aureus*  
351 and concluded that FASII remained a viable drug target in this organism.

352           The relationship between *S. aureus* and long-chain SCUFAs and SCFAs is a complex  
353 one. On one hand these fatty acids in the skin and other tissues form part of the innate defense  
354 system of the host due to their antimicrobial activities [54-56]. Very closely related structures  
355 can either be inhibitory to growth at low concentrations, or can have little effect on growth at  
356 relatively high concentrations [39, 57-59]. For example C16:1 $\Delta$ 6 and C16:1 $\Delta$ 9 are highly  
357 inhibitory whereas C18:1 $\Delta$ 9 and C18 are not inhibitory and are actually incorporated into the  
358 phospholipids by this pathogen [39].

359           The enzyme fatty acid kinase (Fak) responsible for incorporation of extracellular fatty  
360 acids into *S. aureus* phospholipids [41], is also a critical regulator of virulence factor expression  
361 [60], and biofilm formation [61]. Fak phosphorylates extracellular fatty acids for incorporation  
362 into *S. aureus* membrane phospholipids [41]. FakA is a protein with an ATP-binding domain that  
363 interacts with FakB1 and FakB2 proteins that bind SCFAs and SCUFAs preferentially  
364 respectively. Fatty acid kinase activity producing FakB (acyl-PO<sub>4</sub>) was proposed to be involved  
365 in the control of virulence gene expression. Interestingly FakB2 shows a high degree of  
366 specificity for C18:1 $\Delta$ 9, a fatty acid not produced by *S. aureus*, and may act as a sensor for the  
367 host environment via the abundant mammalian fatty acid C18:1 $\Delta$ 9 [41], which is subsequently  
368 incorporated into the membrane lipids.

369 Besides occurring in membrane phospholipids and glycolipids fatty acids are present  
370 in lipoproteins at their N terminus in the form of an N-acyl-S-diacyl-glycerol cysteine residue  
371 and an additional acyl group amide linked to the cysteine amino group [62]. It is estimated that  
372 there are 50-70 lipoproteins in *S. aureus*, many of them involved in nutrient acquisition.  
373 Additionally, lipoproteins contribute important microbe-associated molecular patterns that bind  
374 to Toll-like receptors and activate innate host defense mechanisms. Recently, Nguyen et al. [63]  
375 have shown that when *S. aureus* is fed SCUFAs they are incorporated into lipoproteins and the  
376 cells have an increased toll-like receptor 2- dependent immune stimulating activity, which  
377 enhances recognition by the immune defense system.

378 **Changes in staphyloxanthin in cells grown under different conditions with different**  
379 **membrane fatty acid compositions**

380 The carotenoid staphyloxanthin is a unique *S. aureus* membrane component that  
381 affects membrane permeability, defense against reactive oxygen species, and is a potential drug  
382 target. It appeared that cells grown in media encouraging a high proportion of BCFAs or in  
383 serum resulting in high SCUFAs, both of which would be expected to increase membrane  
384 fluidity, tended to have higher staphyloxanthin contents. However, despite having high amounts  
385 of fluidizing BCFAs or SCUFAs, cells grown in MH broth or serum had cellular membranes that  
386 were significantly less fluid. Thus it may be inferred that the pigment staphyloxanthin could  
387 actually be preventing the membrane from becoming hyper fluid under the particular growth  
388 conditions which yield an unusually high amounts of BCFAs or SCUFAs. These conditions may  
389 thus result in staphylococcal cells which have a better chance at surviving against oxidative  
390 stress and host defense peptides [20]. However this relationship is likely to be complex in that  
391 LB-grown cells that had high BCFAs did not have high carotenoid levels, and the phenomenon

392 deserving of more detailed investigation. Interestingly, in the biosynthesis of staphyloxanthin,  
393 the end step involves an esterification of the glucose moiety with the carboxyl group of anteiso  
394 C15:0 by the activity of the enzyme acyltransferase CrtO [16]. Thus the availability of specific  
395 fatty acid precursors and the lipid metabolism may play a significant role in pigment production.

396 **Plasticity of *S. aureus* membrane lipid composition and its possible ramifications in**  
397 **membrane biophysics and virulence**

398           Given the crucial role of the biophysics of the membrane in all aspects of cell  
399 physiology, such radical changes in the membrane lipid profile can have significant but as yet  
400 undocumented impacts on critical functional properties of cells such as virulence factor  
401 production, susceptibilities to antimicrobials and tolerance of host defenses. It is important to  
402 assess the biophysical and functional properties of the membranes of the cells with such radically  
403 different fatty acid compositions. Although BCFAs and SCUFAs both increase membrane  
404 fluidity, they do not yield cells with identical morphologies [14], or fitness for tolerating cold  
405 stress [64]. Also a *S. aureus* fatty acid auxotroph created by inactivation of acetyl coenzyme A  
406 carboxylase (*AccD*) was not able to proliferate in mice, where it would have access to SCFAs  
407 and SCUFAs [65]. Due to the ability of a pathogen to adapt and undergo dramatic alterations  
408 when subjected to a host environment, there is a growing appreciation in the research community  
409 for the fact that the properties of the organism grown *in vivo* are probably very different from  
410 when it is grown *in vitro*. This distinction may have a huge impact on critical cellular attributes  
411 controlling pathogenesis and resistance to antibiotics. Expression of virulence factors is  
412 significantly different in serum-grown organisms [28], and there are global changes in gene  
413 expression when *S. aureus* is grown in blood [66]. *S. aureus* grown in serum or blood will have

414 different membrane lipid compositions than cells grown in laboratory media and this may have a  
415 significant impact on the expression of virulence factors and pathogenesis of the organism.

416 We have demonstrated a hitherto poorly recognized growth environment-dependent  
417 plasticity of *S. aureus* membrane lipid composition. The balance of BCFAs and SCFAs was  
418 affected significantly by the variations in laboratory medium in which the organism grew.  
419 SCUFAs became a major membrane fatty acid component when the organism was grown in  
420 serum. These findings speak to the properties of pathogens grown *in vitro* versus *in vivo*. In 1960  
421 Garber [67] considered the host as the growth medium and the importance of the properties of  
422 the pathogen at the site of infection. There has been a renewed appreciation of this in recent  
423 years [68]. Massey et al. [69] showed that *S. aureus* grown in peritoneal dialysate acquired a  
424 protein coat. Krismer et al. [70] devised a synthetic nasal secretion medium for growth of *S.*  
425 *aureus*. Tn-seq analysis has been used to identify genes essential for survival in infection models  
426 versus rich medium. Citterio et al. [71] reported that the activities of antimicrobial peptides and  
427 antibiotics were enhanced against various pathogenic bacteria by supplementation of the media  
428 with blood plasma to mimic *in vivo* conditions. In order to replicate a membrane fatty acid  
429 composition more closely resembling that of the bacteria growing *in vivo*, it may be desirable to  
430 supplement laboratory media with SCFAs and SCUFAs.

431

432

433

434

435 **References:**

- 436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479
1. Chambers HF, and Deleo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat Rev Microbiol.* 2009; 7: 629–641. PMID: 19680247
  2. Howden BP, Davies JK, Johnson PD, Sinear TP, and Grayson ML. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanism, laboratory detection, and clinical implications. *Clin Microbiol. Rev.* 2010; 23: 99-139. PMID: 20065327
  3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA.* 2007; 298:1763–1771. PMID: 17940231
  4. Zhang YM, and Rock CO. Membrane lipid homeostasis in bacteria. *Nat Rev Microbiol.* 2008; 6: 222-233. PMID: 18264115.
  5. Parsons JB, and Rock CO. Bacterial lipids: metabolism and membrane homeostasis. *Prog Lipid Res.* 2013. 52:249-276. PMID: 23500459
  6. Parsons JB, and Rock CO. Its bacterial fatty acid synthesis a valid target for antibacterial drug discovery? *Curr Opinion Microbiol.* 2011; 14:544-549. PMID: 21862391
  7. Sun, Y, Wilkinson BJ, Standiford TJ, Akinbi HT, and O’Riordan MXD. Fatty acids regulate stress resistance and virulence factor production for *Listeria monocytogenes*. *J Bacteriol.* 2012; 194:5274-5284. PMID: 22843841
  8. Porta A, Török Z, Horvath I, Franceschelli S, Vígth L, et al. Genetic modification of the *Salmonella* membrane physical state alters the pattern of heat shock response. *J Bacteriol.* 2010; 192:1988-1998. PMID: 20139186
  9. Schleifer KH, and Kroppenstedt RM. Chemical and molecular classification of staphylococci. *Soc Appl Bacteriol Symp. Ser.* 1990; 19:9S-24S. PMID: 211906
  10. Singh VK, Hattangady DS, Giotis ES, Singh AK, Chamberlain NR, et al. Insertional inactivation of branched-chain  $\alpha$ -keto acid dehydrogenase in *Staphylococcus aureus* leads to decreased branched-chain membrane fatty acid content and increased susceptibility to certain stresses. *Appl Environ Microbiol.* 2008; 74: 5882-5890. PMID: 18689519
  11. Wilkinson BJ. Biology. In: K. B. Crossley KB, and Archer GL editors. *The staphylococci in human disease.* New York, NY. 1997. pp 1-38.
  12. O’ Leary WM and Wilkinson SG. Gram positive bacteria. In: Ratledge C, Wilkinson SG, editors. *Microbial Lipids Volume 1.* London: Academic Press; 1988. pp. 117-201.

- 480  
481 13. Kaneda T. Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic  
482 significance. *Microbiol Rev.* 1991; 55: 288-302. PMID: 1886522  
483  
484 14. Legendre S, Letellier L, and Shechter E. Influence of lipids with branched-chain fatty  
485 acids on the physical, morphological and functional properties of *Escherichia coli*  
486 cytoplasmic membrane. *Biochim Biophys Acta.* 1980; 602:491-505. PMID: 6776984  
487  
488 15. Willecke K, and Pardee AB. Fatty acid-requiring mutant of *Bacillus subtilis* defective in  
489 branched chain alpha-keto acid dehydrogenase. *J Biol Chem.* 1971; 246:5264-5272.  
490 PMID: 4999353  
491  
492 16. Pelz A, Wieland KP, Putzbach K, Hentschel P, Albert K, et al. Structure and biosynthesis  
493 of staphyloxanthin from *Staphylococcus aureus*. *J Biol Chem.* 2005; 280: 32493-32498.  
494 PMID: 16020541  
495  
496 17. Wisniewska AJ, Widomska J, and Subczynski WK. Carotenoid membrane interactions in  
497 liposomes: effect of dipolar, monopolar, and non – polar carotenoids. *Acta Biochem Pol.*  
498 2006; 53: 475-484. PMID: 16964324  
499  
500 18. Bramkamp M, and Lopez D. Exploring the existence of lipid rafts in bacteria. *Microbiol*  
501 *Mol Biol Rev.* 2015; 79:81-100. PMID: 25652542  
502  
503 19. Clauditz A, Resch A, Wieland KP, Peschel A, and Gotz F. Staphyloxanthin plays a role  
504 in the fitness of *Staphylococcus aureus* and its ability to cope with oxidative stress. *Infect*  
505 *Immun.* 2006; 74: 4950-4953. PMID: 16861688  
506  
507 20. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, et al. *Staphylococcus aureus*  
508 gold pigment impairs neutrophil killing and promotes virulence through its antioxidant  
509 activity. *J Exp Med.* 2005; 202: 209-215. PMID: 16009720  
510  
511 21. Liu CI, Liu GY, Song Y, Yin F, Hensler ME, et al. Cholesterol biosynthesis inhibitor  
512 blocks *Staphylococcus aureus* virulence. *Science.* 2008; 319: 1391-1394. PMID:  
513 18276850  
514  
515 22. Campbell J, Singh AK, Santa Maria Jr JP, Kim Y, Brown S, et al. Synthetic lethal  
516 compound combinations reveal a fundamental connection between wall teichoic acid and  
517 peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem. Biol.* 2011; 6:106–16.  
518 PMID: 20961110  
519  
520 23. Muthaiyan A, Silverman JA, Jayaswal RK, and Wilkinson BJ. Transcriptional profiling  
521 reveals that daptomycin induces the *Staphylococcus aureus* cell wall stress stimulon and  
522 genes responsive to membrane depolarization. *Antimicrob Agents Chemother.* 2008; 52:  
523 980–990. PMID: 18086846  
524

- 525 24. Song Y, Lunde CS, Benton BM and Wilkinson BJ. Studies on the mechanism of  
526 telavancin decreased susceptibility in a laboratory –derived mutant. *Microbial Drug Res.*  
527 2013; 19: 247-255. PMID: 23551248  
528
- 529 25. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility  
530 testing for bacteria that grow aerobically; approved standard, 7th ed. M7.A7. Clinical and  
531 Laboratory Standards Institute, Wayne, PA. 2006.  
532
- 533 26. Zhu K, Bayles DO, Xiong A, Jayaswal RK, and Wilkinson BJ. Precursor and temperature  
534 modulation of fatty acid composition and growth of *Listeria monocytogenes* cold-  
535 sensitive mutants with transposon-interrupted branched-chain alpha-keto acid  
536 dehydrogenase. *Microbiology.* 2005; 151:615-623. PMID: 15699210.  
537
- 538 27. Ray B, Ballal A, and Manna AC. Transcriptional variation of regulatory and virulence  
539 genes due to different media in *Staphylococcus aureus*. *Microb Pathog.* 2009; 47:94-100.  
540 PMID: 19450677  
541
- 542 28. Oogai Y, Matsuo M, Hashimoto M, Kato F, Sugai M, et al. Expression of virulence  
543 factors by *Staphylococcus aureus* grown in serum. *Appl Environ Microbiol.* 2011;  
544 77:8097-105. PMID: 21926198  
545
- 546 29. Missiakas D, and Schneewind O. Growth and laboratory maintenance of *Staphylococcus*  
547 *aureus*. *Current Protocols in Microbiol.* 2013; DOI: 10.1002/9780471729259. PMID:  
548 2340813  
549
- 550 30. Yao J, and Rock CO. How bacterial pathogens eat host lipids: implications for the  
551 development of fatty acid synthesis therapeutics. *J Biol Chem.* 2015; doi:  
552 10.1074/jbc.R114.636241  
553
- 554 31. Chambers HF. The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis.*  
555 2001; 7:178-182. PMID: 11294701  
556
- 557 32. Moran GJ, A. Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, et al.  
558 Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N*  
559 *Engl J Med.* 2006; 355:666–674.  
560
- 561 33. Fey PD, Endres JL, Yajjala VK, Yajjala K, Widhelm TJ, et al. A genetic resource for  
562 rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus*  
563 *genes*. *MBio.* 2012; 12: e00537-12. PMID: 23404398  
564
- 565 34. Novick RP. Genetic systems in staphylococci. *Methods Enzymol.* 1991; 204: 587–636.  
566 PMID: 1658572  
567
- 568 35. Davis AO, O'Leary JO, Muthaiyan A, et al. Characterization of *Staphylococcus aureus*  
569 mutants expressing reduced susceptibility to common house-cleaners. *J Appl Microbiol.*  
570 2005; 98:364–72. PMID:15659191






- 571  
572 36. Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, et al. Carotenoid-related  
573 alteration of cell membrane fluidity impacts *Staphylococcus aureus* susceptibility to host  
574 defense peptides. *Antimicrob Agents Chemother.* 2011; 55:526-531. PMID: 21115796  
575
- 576 37. Annous BA, Becker LA, Bayles DO, Labeda DP, and Wilkinson BJ. Critical role of  
577 anteiso-C<sub>15:0</sub> fatty acid in the growth of *Listeria monocytogenes* at low  
578 temperatures. *Appl Environ Microbiol.* 1997; 63:3887-3894.  
579
- 580 38. Edgcomb MR, Sirimanne S, Wilkinson BJ, Drouin P, and Morse RP. Electron  
581 paramagnetic resonance studies of the membrane fluidity of the foodborne pathogenic  
582 psychrotroph *Listeria monocytogenes*. *Biochim Biophys Acta.* 2000; 1463:31-42.  
583
- 584 39. Parsons JB, Yao J, Frank MW, Jackson P, and Rock CO. Membrane disruption by  
585 antimicrobial fatty acids releases low molecular weight proteins from *Staphylococcus*  
586 *aureus*. *J Bacteriol.* 2012; 194: 5294–5304. PMID: 22843840  
587
- 588 40. Townsend, D.E., and B.J. Wilkinson. 1992. Proline transport in *Staphylococcus aureus*: a  
589 high-affinity system and a low-affinity system involved in osmoregulation. *J Bacteriol.*  
590 174:2702–2710. PMID: 1556088
- 591
- 592 41. Parsons J, Frank M, Jackson P, Subramanian C, and Rock CO. Incorporation of  
593 extracellular fatty acids by a fatty acid kinase-dependent pathway in *Staphylococcus*  
594 *aureus*. *Mol Microbiol.* 2014; 92: 234–245.  
595
- 596 42. Parsons JB, Frank MW, Subramanian C, Saenkham P, and Rock CO. Metabolic basis for  
597 the differential susceptibility of Gram – positive pathogens for fatty acid synthesis  
598 inhibitors. *Proc Natl Acad Sci. USA.* 2011; 108: 15378-15383. PMID: 21876172  
599
- 600 43. Payne JW, Gilvarg C. Size restriction on peptide utilization in *Escherichia coli*. *J Biol*  
601 *Chem.* 1968; 243(23):6291–9. PMID: 26629334  
602
- 603 44. Amezaga MR, Davidson I, McLaggan D, Verheul A, Abee T, Booth IR. The role of  
604 peptide metabolism in the growth of *Listeria monocytogenes* ATCC 23074 at high  
605 osmolarity. *Microbiology.* 1995; 141:41–49. PMCID: PMC167277  
606
- 607 45. Hiron A, Borezee-Durant E, Piard JC, Juillard V. Only one of four oligopeptide transport  
608 systems mediates nitrogen nutrition in *Staphylococcus aureus*. *J Bacteriol.* 2007;  
609 189:5119–5129.10.1128/JB.00274-07. PMID:17496096  
610
- 611 46. Kaiser J.C., Sen S., Wilkinson B.J., Henrichs D. E. BrnQ1 in *Staphylococcus aureus* is a  
612 Leu/Val transporter required for determining branched-chain membrane fatty acids  
613 content. *Abstr. Annu. Mtg. Am. Soc. Microbiol.* 2016.  
614

- 615 47. Qiu, X, Choudhry AE, Janson CA, Grooms M, Daines RA, et al. X Crystal structure and  
616 substrate specificity of  $\beta$ -ketoacyl carrier protein synthase III (FabH) from  
617 *Staphylococcus aureus*. Protein Sci. 2007; 14: 2087-2094. PMID: 15987898  
618
- 619 48. Altenbern RA. Cerulenin-inhibited cells of *Staphylococcus aureus* resume growth when  
620 supplemented with either a saturated or an unsaturated fatty acid. Antimicrob Agents  
621 Chemother. 1977; 11: 574–576 PMID: 856007  
622
- 623 49. Holman R, Adams C, Nelson R, Grater S, Jaskiewicz J, et al. Patients with anorexia  
624 nervosa demonstrate deficiencies of selected essential fatty acids, compensatory changes  
625 in nonessential fatty acids and decreased fluidity of plasma lipids. J Nutr. 1995; 125:901–  
626 907. PMID: 7722693.  
627
- 628 50. Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S, et al. Serum fatty acid  
629 levels, dietary style and coronary heart disease in three neighboring areas in Japan: the  
630 Kumihama study. Br J Nutr. 2003; 89:267–272. PMID: 12575911  
631
- 632 51. Shimomura, Y, Sugiyama S, Takamura T, Kondo T, and Ozawa T. Quantitative  
633 determination of the fatty acid composition of human serum lipids by high-performance  
634 liquid chromatography. J Chromatogr. 1986; 383:9–17. PMID: 3818849  
635
- 636 52. Psychogios N, Hau DD, Peng J, Guo AC, Mandal AC, et al. The human serum  
637 metabolome. PLoS ONE. 2011; 6(2): e16957. PMID: 21359215  
638
- 639 53. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, et al. Type II fatty acid  
640 synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature. 2009;  
641 458: 83-86. PMID: 19262672  
642
- 643 54. Clarke SR, Mohamed R, Bian L, Routh AF, Kokai-Kun JF, Mond JJ, et al.  
644 The *Staphylococcus aureus* surface protein IsdA mediates resistance to innate defenses of  
645 human skin. Cell Host Microbe. 2007; 1:199–212. doi: 10.1016/j.chom.2007.04.005  
646 PMID:18005699  
647
- 648 55. Stewart ME. Sebaceous gland lipids. Semin Dermatol. 1992; 11:100–105.  
649 PMID:1498012  
650
- 651 56. Hamosh M. Protective function of proteins and lipids in human milk. Biol Neonate. 1998;  
652 74:163–176. PMID: 9691157  
653
- 654 57. Takigawa H, Nakagawa H, Kuzukawa M, Mori H, Imokawa G. Deficient production of  
655 hexadecenoic acid in the skin is associated in part with the vulnerability of atopic  
656 dermatitis patients to colonization by *Staphylococcus aureus*. Dermatology.  
657 2005; 211:240–248. 10.1159/000087018. PMID: 16205069  
658


- 659 58. Cartron ML, England SR, Chiriac AI, Josten M, Turner R, et al. Bactericidal activity of  
660 the human skin fatty acid *cis*-6-hexadecanoic acid on *Staphylococcus aureus*. Antimicrob  
661 Agents Chemother. 2014; 58:3599-3609. PMID: 24709265  
662
- 663 59. Kenny JG, Ward D, Josefsson E, Jonsson IM, Hinds J, Lindsay JA, et al. The  
664 *Staphylococcus aureus* response to unsaturated long chain free fatty acids: survival  
665 mechanisms and virulence implications. PLOS One. 2009. DOI:  
666 10.1371/journal.pone.0004344  
667
- 668 60. Bose, JL, Daly SM, Hall RR, and Bayles KW. Identification of the *vfrAB* operon in  
669 *Staphylococcus aureus*: A novel virulence factor regulatory locus. Infect Immun. 2014;  
670 82: 1813–1822.  
671
- 672 61. Sabirova JS, Hernalsteens JP, De Backer S, et al. Fatty acid kinase A is an important  
673 determinant of biofilm formation in *Staphylococcus aureus* USA300. BMC Genomics.  
674 2015; 16:861. Doi: 10.1186/s12864-015-1956-8. PMID: 26502874  
675
- 676 62. Stoll H, Dengjel J, Nerz C & Götz F. *Staphylococcus aureus* deficient in lipidation of  
677 prelipoproteins is attenuated in growth and immune activation. Infect Immun. 2005; 73:  
678 2411–2423. PMCID: PMC1087423  
679
- 680 63. Nguyen MH, Hanzelmann D, Härtner T, Peschel A, Götz F. Skin-specific unsaturated  
681 fatty acid boost *Staphylococcus aureus* innate immune response. Infect Immun. 2015;  
682 doi:10.1128/IAI.00822-15  
683
- 684 64. Silbert DF, Ladenson RC, and Honegger JL. The unsaturated fatty acid requirement in  
685 *Escherichia coli*. Temperature dependence and total replacement by branched-chain fatty  
686 acids. Biochim Biophys Acta. 1973; 311: 349-361. PMID: 4580982  
687
- 688 65. Parsons JB, Frank MW, Rosch JW, and Rock CO. *Staphylococcus aureus* fatty acid  
689 auxotrophs do not proliferate in mice. Antimicrob Agents Chemother. 2013; 57: 5729–  
690 5732. PMID: 23979734.  
691
- 692 66. Malachowa N, Whitney AR, Kobayashi SD, Sturdevant DE, Kennedy AD, et al. Global  
693 changes in *Staphylococcus aureus* gene expression in human blood. PLoS ONE. 2011;  
694 6:e18617. PMID: 21525981  
695
- 696 67. Garber ED. The host as a growth medium. Annals of the New York Academy of  
697 Sciences.1960; 88:1187–1194. doi: 10.1111/j.1749-6632.  
698
- 699 68. Brown SA, Palmer KL, Whiteley M. Revisiting the host as a growth medium. Nat Rev  
700 Microbiol. 2008; 6: 657–666. doi: 10.1038/nrmicro1955  
701
- 702 69. Massey RC, Dissanayeke SR, Cameron B, Ferguson D, Foster TJ, and Peacock SJ.  
703 Functional blocking of *Staphylococcus aureus* adhesins following growth in ex vivo  
704 media. Infect Immun. 2002; 70:5339-5345. PMID: 12228257

- 705  
706 70. Krismer B, Liebeke M, Janek D, Nega M, Rautenberg M, Hornig G, et al. Nutrient  
707 limitation governs *Staphylococcus aureus* metabolism and niche adaptation in the human  
708 nose. PLoS Pathogens. 2014;10: e1003862 doi: 10.1371/journal.ppat.1003862  
709  
710 71. Citterio L, Franzyk H, Palarasah Y, Andersen TE, Mateiu RV, Gram L. Improved  
711 in vitro evaluation of novel antimicrobials: potential synergy between human plasma and  
712 antibacterial peptidomimetics, AMPs and antibiotics against human pathogenic bacteria.  
713 Research in Microbiology. 2016: 167: 72-82., 10.1016/j.resmic.2015.10.002  
714


**Figure 1**

<b>BCFA</b>	Anteiso C15:0	
	Iso C15:0	
<b>SCFA</b>	C18:0 (Stearic acid)	
<b>SCUFA</b>	C18:1 $\Delta$ 9 (Oleic acid)	
<b>Staphyloxanthin</b>	$\beta$ -D-glucopyranosyl 1-O-(4,4'-diaponeurosporen-4-oate)-6-O-(12-methyltetradecanoate)	

**Figure 2**



**Figure 3**



**Figure 4**

